Genetic susceptibility to iatrogenic malignancy

Pharmacogenomics

Volumn 6, Issue 6, 2005, Pages 615-628

  Allan, James M ^a   Rabkin, Charles S ^b  

^a UNIVERSITY OF YORK   (United Kingdom)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Anthracycline; Ataxia telangiectasia; Chemotherapy; Cytochrome P450; Epipodophyllotoxin; Fanconi anemia; Glutathione S transferase; Li Fraumeni syndrome; Neurofibromatosis; Nijmegen breakage syndrome; Pharmacogenetics; Radiotherapy; Single nucleotide polymorphism; Thiopurine methyltransferase; Xeroderma pigmentosum

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ANTHRACYCLINE DERIVATIVE; ARGININE; ATM PROTEIN; AZATHIOPRINE; BUSULFAN; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOCHROME P450; DNA; DNA (APURINIC OR APYRIMIDINIC SITE) LYASE; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; EPIPODOPHYLLOTOXIN; ETOPOSIDE; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE M1; IFOSFAMIDE; MELPHALAN; METHYLTRANSFERASE; MIXED LINEAGE LEUKEMIA PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; NUCLEOTIDE; OXIDOREDUCTASE; PROTEIN MSH2; RAD51 PROTEIN; TIOGUANINE; UNINDEXED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ALLELE; BONE MARROW TOXICITY; BRAIN TUMOR; BREAST CANCER; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL DEATH; DNA REPAIR; EARLY DIAGNOSIS; ENZYME ACTIVITY; EXCISION REPAIR; GENE LOCUS; GENETIC EPIDEMIOLOGY; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HIGH RISK POPULATION; HUMAN; IATROGENIC DISEASE; LEUKEMIA; MALIGNANT NEOPLASTIC DISEASE; MISMATCH REPAIR; MYELOID LEUKEMIA; NEUROFIBROMATOSIS; PREDICTION; REVIEW; SIGNAL TRANSDUCTION;

ALLELES; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FORECASTING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; NEOPLASMS, SECOND PRIMARY; RISK FACTORS;

ATAXIA TELANGIECTASIA;

EID: 25144480988     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.6.6.615     Document Type: Review

References (103)

1. Schoch C, Kern W, Schnittger S, Hiddemann W, Haferlach T: Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. leukemialeukemia 18, 120-125 (2004).
2. Goldstone AH, Burnett AK, Avivi I et al.: Secondary acute myeloid leukemia has a worse outcome than de novo AML, even taking into account cytogenetics and age. AML 10, 11, 12 MRC Trials. Blood 100, 88a, Abstract 322 (2002).
3. Travis LB: Therapy-associated solid tumors. Acta Oncol. 41, 323-333 (2002).
4. Dores GM, Metayer C, Curtis RE et al.: Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J. Clin. Oncol. 20, 3484-3494 (2002).
5. Allan JM, Wild CP, Rollinson S et al.: Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia. Proc. Natl Acad. Sci. USA 98, 11592-11597 (2001).
6. Worrillow LJ, Travis LB, Smith AG et al.: An intron splice acceptor polymorphism in hMSH2 and risk of leukemia after treatment with chemotherapeutic alkylating agents. Clin. Cancer Res. 9, 3012-3020 (2003).
7. Felix CA: Secondary leukaemias induced by topoisomerase-targeted drugs. Biochim. Biophys. Acta. 1400, 233-255 (1998).
8. Seidegard J, Ekstrom G: The role of human glutathione transferases and epoxide hydrolases in the metabolism of xenobiotics. Environ. Health. Perspect. 105, 791-799 (1997).
9. Pandya U, Srivastava SK, Singhal SS et al.: Activity of allelic variants of π class human glutathione S-transferase toward chlorambucil. Biochem. Biophys. Res. Comm. 278, 258-262 (2000).
10. Dirven HA, Megens L, Oudshoorn MJ, Dingemanse MA, Vanommen B, Vanbladeren PJ: Glutathione conjugation of the cytostatic drug ifosfamide and the role of human glutathione S-transferases. Chem. Res. Toxicol. 8, 979-986 (1995).
11. Czwerwinski M, Gibbs JP, Slattery JT: Busulfan conjugation by glutathione S-transferases α, μ and π. Drug Metab. Dispos. 24, 1015-1019 (1996).
12. Ban N, Takahashi Y, Takayama T et al.: Transfection of glutathione S-transferase (GST)-π antisense complementary DNA increases the sensitivity of a colon cancer cell line to adriamycin, cisplatin, melphalan, and etoposide. Cancer Res. 56, 3577-3582 (1996).
13. Kuga T, Sakamaki S, Matsunaga T et al.: Fibronectin fragment-facilitated retroviral transfer of the glutathione-S-transferase π gene into CD34+ cells to protect them against alkylating agents. Hum. Gene Ther. 8, 1901-1910 (1997).
14. Niitsu Y, Takahashi Y, Ban N et al.: A proof of glutathione S-transferase-π-related multidrug resistance by transfer of antisense gene to cancer cells and sense gene to bone marrow stem cell. Chem. Biol. Interact. 111-112, 325-332 (1998).
15. Ishimoto TM, Ali-Osman F: Allelic variants of the human glutathione S-transferase P1 gene confer differential cytoprotection against anticancer agents in Escherichia coli. Pharmacogenetics 12, 543-553 (2002).
16. Seidegard J, Vorachek WR, Pero WR, Pearson WR: Hereditary differences in the expression of the human glutathione transferase active on trans-stilbene oxide are due to a gene deletion. Proc. Natl Acad. Sci. USA 85, 7293-7297 (1988).
17. Sprenger R, Schlagenhaufer R, Kerb R et al.: Characterization of the glutathione S-transferase GSTT1 deletion: discrimination of all genotypes by polymerase chain reaction indicates a trimodular genotype-phenotype correlation. Pharmacogenetics 10, 557-565 (2000).
18. Mertens AC, Mitby PA, Radloff G et al.: XRCC1 and glutathione-S-transferase gene polymorphisms and susceptibility to radiotherapy-related malignancies in survivors of Hodgkin disease. Cancer 101, 1463-1472 (2004).
19. Sasai Y, Horiike S, Misawa S et al.: Genotype of glutathione S-transferase and other genetic configurations in myelodysplasia. Leuk. Res. 23, 975-981 (1999).
20. Haase D, Binder C, Bunger J et al.: Increased risk for therapy-associated hematologic malignancies in patients with carcinoma of the breast and combined homozygous gene deletions of glutathione transferases M1 and T1. Leuk. Res. 26, 249-254 (2002).
21. Rollinson S, Roddam P, Kane E et al.: Polymorphic variation within the glutathione S-transferase genes and risk of adult acute leukemia. Carcinogenesis 21, 43-47 (2000).
22. Woo MH, Shuster JJ, Chen C et al.: Glutathione S-transferase genotypes in children who develop treatment-related acute myeloid malignancies. Leukaemia 14, 232-237 (2000).
23. Ali-Osman F, Akande O, Antoun G, Mao J-X, Boulamwini J: Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase π gene variants. J. Biol. Chem. 15, 10004-10012 (1997).
24. 105Val polymorphism. Cancer Res. 60, 5621-5624 (2000).
25. Hohaus S, Di Ruscio A, Di Febo A et al.: Glutathione S-transferase P1 genotype and prognosis in Hodgkin's lymphoma. Clin. Cancer Res. 11, 2175-2179 (2005).
26. Jazbec J, Aplenc R, Dolzan V, Debeljak M, Jereb B: GST polymorphisms and occurrence of second neoplasms after treatment of childhood leukemia. Leukaemia 17, 2540-2542 (2003).
27. Reinemer P, Dirr HW, Ladenstein R, Huber R et al.: Three-dimensional structure of class p glutathione S-transferase from human placenta in complex with S-hexylglutathione at 2.8 A resolution. J. Mol. Biol. 227, 214-226 (1991).
28. Zimniak P, Nanduri B, Pikula S et al.: Naturally-occurring human glutathione S-transferase GSTP1-1 isoforms with isoleucine and valine in position 104 differ in enzymic properties. Eur. J. Biochem. 224, 893-899 (1994).
29. Johansson A-S, Stenberg G, Widersten M, Mannervik B: Structure-activity relationships and thermal stability of human glutathione transferase P1-1 governed by the H-site residue 105. J. Mol. Biol. 278, 687-698 (1998).
30. Srivastava SK, Singhal SS, Hu X, Awasthi YC, Zimniak P, Singh SV: Differential catalytic efficiency of allelic variants of human glutathione S-transferase π in calalyzing the glutathione conjugation of thiotepa. Arch. Biochem. Biophys. 366, 89-94 (1999).
31. Blanco JG, Edick MJ, Relling MV: Etoposide induces chimeric MLL gene fusions. FASEB J. 18, 173-175 (2004).
32. + cells and remain stable after clonal expansion. Blood 105, 2124-2131 (2005).
33. Gutierrez PL: The role of NaD(P)H oxidoreductase (DT-diaphorase) in the bioactivation of quinone-containing antitumor agents: a review. Free Radic. Biol. Med. 29, 263-275 (2000).
34. Cadenas E: Antioxidant and prooxidant functions of DT-diaphorase in quinone metabolism. Biochem. Pharmacol. 49, 127-140 (1995).
35. Larson RA, Wang Y, Banerjee M et al.: Prevalence of the inactivating 609C>T polymorphism in the NaD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. Blood 94, 803-807 (1999).
36. Naoe T, Takeyama K, Yokozawa T et al.: Analysis of genetic polymorphism in NQO1, GST-M1, GST-T1, and CYP3A4 in 469 Japanese patients with therapy-related leukemia/myelodysplastic syndrome and de novo acute myeloid leukemia. Clin. Cancer Res. 6, 4091-4095 (2000).
37. Smith MT, Wang Y, Skibola CF et al.: Low NaD(P)H:quinone oxidoreductase activity is associated with increased risk of leukemia leukemia with MLL translocations in infants and children. Blood 100, 4590-4593 (2002).
38. Blanco JG, Edick MJ, Hancock ML et al.: Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies. Pharmacogenetics 12, 605-611 (2002).
39. Seedhouse C, Bainton R, Lewis M, Harding A, Russell N, Das-Gupta E: The genotype distribution of the XRCC1 gene indicates a role for base excision repair in the development of therapy-related acute myeloblastic leukemia. Blood 100, 3761-3766 (2002).
40. Echlin-Bell DR, Smith LL, Li L et al.: Polymorphisms in the MLL breakpoint cluster region (BCR). Hum. Genet. 113, 80-91 (2003).
41. Felix CA, Walker AH, Lange BJ et al.: Association of CYP3A4 genotype with treatment-related leukemia. Proc. Natl Acad. Sci. USA 95, 13176-13181 (1998).
42. Lopes LF, Piccoli Fde S, Paixao VA et al.: Association of CYP3A4 genotype with detection of Vγ/Jβ trans-rearrangements in the peripheral blood leukocytes of pediatric cancer patients undergoing chemotherapy for ALL. Leuk. Res. 28, 1281-1286 (2004).
43. Roddam PL, Allan JM, Rollinson S et al.: Poor metabolizer status at the cytochrome P450 2C9 and 2D6 loci does not modulate susceptibility to therapy-related acute myeloid leukemia. Br. J. Haematol. 121, 192-194 (2003).
44. McLeod HL, Siva C: The thiopurine S-methyltransferase gene locus-implications for clinical pharmacogenomics. Pharmacogenomics 3, 89-98 (2002).
45. Yates CR, Krynetski EY, Loennechen T et al.: Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann. Intern. Med. 126, 608-614 (1997).
46. Evans WE, Horner M, Chu YQ, Kalwinsky D, Roberts WM: Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J. Pediatr. 119, 985-989 (1991).
47. McLeod HL, Miller DR, Evans WE: Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient. Lancet 341, 1151 (1993).
48. Relling MV, Hancock ML, Rivera GK et al.: Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J. Natl Cancer Inst. 91, 2001-2008 (1999).
49. Black AJ, McLeod HL, Capell HA et al.: Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann. Intern. Med. 129, 716-718 (1998).
50. McLeod HL, Krynetski EY, Relling WV, Evans WE: Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. leukemia 14, 567-572 (2000).
51. Relling MV, Rubnitz JE, Rivera GK et al.: High incidence of secondary brain tumors after radiotherapy and antimetabolites. Lancet 354, 34-39 (1999).
52. Thomsen JB, Schroder H, Kristinsson J et al.: Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells: relation to thiopurine metabolism. Cancer 86, 1080-1086 (1999).
53. Saidi RF, Dudrick PS, Goldman MH: Colorectal cancer after renal transplantation. Transplant. Proc. 35, 1410-1412 (2003).
54. Birkeland SA, Lokkegaard H, Storm HH: Cancer risk in patients on dialysis and after renal transplantation. Lancet 355, 1886-1887 (2000).
55. Allan JM, Smith AG, Wheatley K et al.: Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy. Blood 104, 3872-3877 (2004).
56. Grant DF, Bessho T, Reardon JT: Nucleotide excision repair of melphalan monoadducts. Cancer Res. 58, 5196-5200 (2000).
57. Reardon JT, Vaisman A, Chaney SG, Sancar A: Efficient nucleotide excision repair of cisplatin, oxaliplatin, and bis-acetoamine-dichlororcyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts. Cancer Res. 59, 3968-3971 (1999).
58. Brewster AM, Alberg AJ, Strickland PT, Hoffman SC, Helzlsouer K: XPD polymorphism and risk of subsequent cancer in individuals with nonmelanoma skin cancer. Cancer Epidemiology Biomarkers and Prevention 13, 1271-1275 (2004).
59. Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei DD, Groshen S, Lenz HJ: A xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum based chemotherapy in patients with advanced colorectal cancer. Cancer Res. 61, 8654-8658 (2001).
60. Colussi C, Fiumicino S, Giuliani A et al.: 1,2-dimethylhydrazine-induced colon carcinoma and lymphoma in msh2(-/-) mice. J. Natl Cancer Inst. 93, 1534-1540 (2001).
61. 6-methylguanine built into a unique site in a viral genome. Proc. Natl Acad. Sci. USA 81, 6271-6275 (1984).
62. Infante-Rivard C, Mathonnet G, Sinnett D: Risk of childhood leukemia associated with diagnostic irradiation and polymorphisms in DNA repair genes. Environ. Health Perspect. 108, 495-498 (2000).
63. Infante-Rivard C: Diagnostic X-rays, DNA repair genes and childhood acute lymphoblastic leukemia. Health Phys. 85, 60-64 (2003).
64. Seedhouse C, Faulkner R, Ashraf N, Das-Gupta E, Russell N: Polymorphisms in genes involved in homologous recombination repair interact to increase the risk of developing acute myeloid leukemia. Clin. Cancer Res. 10, 2675-2680 (2004).
65. Hadi MZ, Coleman MA, Fidelis K, Mohrenweiser HW, Wilson DM 3rd: Functional characterization of Ape1 variants identified in the human population. Nucleic Acids Res. 28, 3871-3879 (2000).
66. Hu JJ, Smith TR, Miller MS, Mohrenweiser HW, Golden A, Case LD: Amino acid substitution variants of APE1 and XRCC1 genes associated with ionizing radiation sensitivity. Carcinogenesis 22, 917-922 (2001).
67. Bader JL: Neurofibromatosis and cancer. Ann. NY Acad. Sci. 486, 57-65 (1986).
68. Legius E, Marchuk DA, Collins FS, Glover TW: Somatic deletion of the neurofibromatosis Type 1 gene in a neurofibrosarcoma supports a tumor suppressor gene hypothesis. Nature Genet. 3, 122-126 (1993).
69. Colman SD, Williams CA, Wallace MR: Benign neurofibromas in Type 1 neurofibromatosis (NF1) show somatic deletions of the NF1 gene. Nature Genet. 11, 90-92 (1995).
70. Shannon KM, O'Connell P, Martin GA et al.: Loss of normal NF1 allele from the bone marrow of children with Type 1 neurofibromatosis and malignant myeloid disorders. N. Engl. J. Med. 330, 597-601 (1994).
71. Maris JM, Wiersma SR, Mahgoub N et al.: Monosomy 7 myelodysplastic syndrome and other second malignant neoplasms in children with neurofibromatosis Type 1. Cancer 79, 1438-1446 (1997).
72. Mahgoub N, Taylor BR, Le Beau MM et al.: Myeloid malignancy induced by alkylating agents in Nf1 mice. Blood 93, 3617-3623 (1999)
73. Limacher JM, Frebourg T, Natarajan-Ame S, Bergerat JP: Two metachronous tumors in the radiotherapy fields of a patient with Li-Fraumeni syndrome. Int. J. Cancer 96, 238-242 (2001).
74. Felix CA, Hosler MR, Provisor D et al.: The p53 gene in pediatric therapy-related leukemia and myelodysplasia. Blood 87, 4376-4381 (1996).
75. Hisada M, Garber JE, Fung CY, Fraumeni JF Jr, Li FP: Multiple primary cancers in families with Li-Fraumeni syndrome. J. Natl Cancer Inst. 90, 606-611 (1998).
76. Dumont P, Leu JI, Della Pietra AC 3rd, George DL, Murphy M: The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nature Genet. 33, 357-365 (2003).
77. Li X, Dumont P, Della Pietra A, Shetler C, Murphy ME: The codon 47 polymorphism in p53 is functionally significant. J. Biol Chem. (Epub ahead of print) (2005).
78. Neubauer S, Arutyunyan R, Stumm M et al.: Radiosensitivity of ataxia telangiectasia and Nijmegen breakage syndrome homozygotes and heterozygotes as determined by three-color FISH chromosome painting. Radiat. Res. 157, 312-321 (2002).
79. Gutierrez-Enriquez S, Fernet M, Dork T et al.: Functional consequences of ATM sequence variants for chromosomal radiosensitivity. Genes Chromosomes Cancer 40, 109-119 (2004).
80. Makis A, Polychronopoulou S, Haidas S: Osteosarcoma as a second tumor after treatment for primary non-Hodgkin's lymphoma in a child with ataxia-telangiectasia: presentation of a case and review of possible pathogenetic mechanisms. J. Pediatr. Hematol. Oncol. 26, 444-446 (2004).
81. Overberg-Schmidt U, Wegner RD, Baumgarten E et al.: Low-grade non-Hodgkin's lymphoma after high-grade non-Hodgkin's lymphoma in a child with ataxia telangiectasia. Cancer 73, 1522-1525 (1994).
82. Khanna KK: Cancer risk and the ATM gene: a continuing debate. J. Natl Cancer Inst. 92, 795-802 (2000).
83. Pandita TK, Hittelman WN: Increased initial levels of chromosome damage and heterogeneous chromosome repair in ataxia telangiectasia heterozygote cells. Mutat. Res. 310, 1-13 (1994).
84. Barlow C, Eckhaus MA, Schaffer AA, Wynshaw-Boris A: ATM haploinsufficiency results in increased sensitivity to sublethal doses of ionizing radiation in mice. Nature Genet. 21, 359-360 (1999).
85. Smilenov LB, Brenner DJ, Hall EJ: Modest increased sensitivity to radiation oncogenesis in ATM heterozygous versus wild-type mammalian cells. Cancer Res. 61, 5710-5713 (2001).
86. Offit K, Gilad S, Paglin S et al.: Rare variants of ATM and risk for Hodgkin's disease and radiation-associated breast cancers. Clin. Cancer Res. 8, 3813-3819 (2002).
87. Nichols KE, Levitz S, Shannon KE et al.: Heterozygous germline ATM mutations do not contribute to radiation-associated malignancies after Hodgkin's disease. J. Clin. Oncol. 17, 1259-1266 (1999).
88. Broeks A, Russell NS, Floore AN et al.: Increased risk of breast cancer following irradiation for Hodgkin's disease is not a result of ATM germline mutations. Int. J. Radiat. Biol. 76, 693-698 (2000).
89. Shafman TD, Levitz S, Nixon AJ et al.: Prevalence of germline truncating mutations in ATM in women with a second breast cancer after radiation therapy for a contralateral tumor. Genes Chromosomes Cancer 27, 124-129 (2000).
90. Athma P, Rappaport R, Swift M: Molecular genotyping shows that ataxia telangiectasia heterozygotes are predisposed to breast cancer. Cancer Genet. Cytogenet. 92, 130-134 (1996).
91. Olsen JH, Hahnemann JM, Borresen-Dale AL et al.: Cancer in patients with ataxia-telangiectasia and in their relatives in the nordic countries. J. Natl Cancer Inst. 93, 121-127 (2001).
92. Swift M, Morrell D, Massey RB, Chase CL: Incidence of cancer in 161 families affected by ataxia telangiectasia. N. Engl. J. Med. 325, 1831-1836 (1991).
93. Easton DF: Cancer risk in A-T heterozygotes. Int. J. Rad. Biol. 66, S177-S182 (1994).
94. Iannuzzi CM, Atencio DP, Green S, Stock RG, Rosenstein BS: ATM mutations in female breast cancer patients predict for an increase in radiation-induced late effects. Int. J. Radiat. Oncol. Biol. Phys. 52, 606-613 (2002).
95. Angele S, Romestaing P, Moullan N et al.: ATM haplotypes and cellular response to DNA damage: association with breast cancer risk and clinical radiosensitivity. Cancer Res. 63, 8717-8725 (2003).
96. Antoccia A, Ricordy R, Maraschio P, Prudente S, Tanzarella C: Chromosomal sensitivity to clastogenic agents and cell cycle perturbations in Nijmegen breakage syndrome lymphoblastoid cell lines. Int. J. Radiat. Biol. 71, 41-49 (1997).
97. D'Andrea AD, Grompe M: The Fanconi anemia/BRCA pathway. Nature Rev. Cancer 3, 23-34 (2003).
98. Sugita K, Taki T, Hayashi Y et al.: MLL-CBP fusion transcript in a therapy-related acute myeloid leukemia with the t(11;16)(q23;p13) which developed in an acute lymphoblastic leukemia patient with Fanconi anemia. Genes Chromosomes Cancer 27, 264-269 (2000).
99. Auerbach AD, Wolman SR: Carcinogen-induced chromosome breakage in Fanconi's anemia heterozygous cells. Nature 271, 69-71 (1978).
100. Barquinero JF, Barrios L, Ribas M, Egozcue J, Caballin MR: Cytogenetic sensitivity of three Fanconi anemia heterozygotes to bleomycin and ionizing radiation. Cancer Genet. Cytogenet. 124, 80-83 (2001).
101. Rischewski JR, Clausen H, Leber V et al.: A heterozygous frameshift mutation in the Fanconi anemia C gene in familial T-ALL and secondary malignancy. Klin. Padiatr. 212, 174-176 (2000).
102. Steffen J, Varon R, Mosor M et al.: Increased cancer risk of heterozygotes with NBS1 germline mutations in Poland. Int. J. Cancer 111, 67-71 (2004).
103. Dumon-Jones V, Frappart PO, Tong WM et al.: Nbn heterozygosity renders mice susceptible to tumor formation and ionizing radiation-induced tumorigenesis. Cancer Res. 63, 7263-7269 (2003).